Summary of Fortrea (FTRE) Q2 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: $678.2 million, a 4.5% decrease year-over-year primarily due to lower pass-through costs.

Adjusted EBITDA: $58.7 million, up from $54.9 million in the prior year, driven by cost optimization and operational efficiencies.

Net Loss: $13.2 million, significantly improved from a net loss of $374.9 million in the prior year, which included a goodwill impairment charge.

Adjusted Net Income: $22.7 million, compared to $17.6 million in the previous year.

Book-to-Bill Ratio: 1.06x for the quarter, with a trailing 12-month ratio of 1.12x, indicating sustained commercial momentum.

Backlog: $7.8 billion, with cancellations in line with historical trends.

Operating Cash Flow: Positive $28.9 million, up from $21.8 million year-over-year.

Free Cash Flow: Positive $19.9 million, compared to $14.3 million in Q2 2025.

2Strategic Updates and Business Highlights

Fortrea's commercial strategy focuses on "3 Rs": reach, relevance, and repeat, leading to $720.4 million in net new business, primarily in biotech.

The Clinical Pharmacology Services (CPS) segment showed strong performance, contributing to revenue growth.

The company is investing in AI and technology integration through its Fortrea Intelligent Technology (FIT) initiative, aiming to enhance operational efficiency and client outcomes.

Leadership transition occurred with Jason Madlock unable to serve as CFO due to a legal matter; David Smith is acting as interim CFO.

3Forward Guidance and Outlook

Full-year 2026 revenue guidance increased to $2.62 billion - $2.69 billion, with adjusted EBITDA guidance raised to $205 million - $220 million.

Expectations for continued positive free cash flow for the remainder of 2026.

The company remains focused on sustainable growth, margin expansion, and disciplined capital allocation.

4Bad News, Challenges, or Points of Concern

Revenue decline year-over-year due to lower pass-through costs and ongoing headwinds in the Functional Service Provider (FSP) segment.

The CFO transition could pose risks if not managed effectively.

Competitive pressures remain high in the CRO industry, with the need for continuous improvement in commercial execution and operational performance.

5Notable Q&A Insights

Management acknowledged the ongoing FSP drag but highlighted improvements in CPS and a better study mix contributing to margins.

There was discussion on the competitive landscape, indicating a return to rational pricing behaviors in the industry.

AI capabilities are becoming a differentiator in RFP processes, but meaningful commercial impacts from AI adoption are expected to take time.

The company is seeing improved engagement from both pharma and biotech clients, with a focus on diversifying its client base and project types. Overall, Fortrea reported a solid quarter with improved financial metrics and strategic initiatives aimed at enhancing commercial and operational performance, despite facing some challenges in revenue and competitive pressures.